News
Report: Apple Inc. OLED iPhone Production Delayed
According to DigiTimes, citing a report from publication Economic Daily News, the production of Apple's (NASDAQ: AAPL) OLED iPhone has been pushed out to the November to December time frame. Moreover
Report: Apple Inc. OLED iPhone Production Delayed
According to DigiTimes, citing a report from publication Economic Daily News, the production of Apple's (NASDAQ: AAPL) OLED iPhone has been pushed out to the November to December time frame. Moreover
3 Stocks to Buy if the Bull Market Fizzles
You know it's coming. Sooner or later, the current long-in-the-tooth bull market will end -- probably in tandem with an economic downturn. What will you do when it happens? For some, the answer is to
3 Stocks to Buy if the Bull Market Fizzles
You know it's coming. Sooner or later, the current long-in-the-tooth bull market will end -- probably in tandem with an economic downturn. What will you do when it happens? For some, the answer is to
I Still Can't Believe Visa Inc. Spent Over $7 Billion on Share Buybacks
The market capitalization of a great many companies on the stock exchange doesn't total $7 billion. That's a large pile of money. Yet it was that net amount (to be technical, it was $7.06 billion)
5 Signs Blue Apron's High Growth Days Are Over
Meal-kit maker Blue Apron's (NYSE: APRN) public debut in late June was one of the most disappointing IPOs in recent history. The company went public at $10 per share, but it's already shed about a
5 Signs Blue Apron's High Growth Days Are Over
Meal-kit maker Blue Apron's (NYSE: APRN) public debut in late June was one of the most disappointing IPOs in recent history. The company went public at $10 per share, but it's already shed about a
5 Signs Blue Apron's High Growth Days Are Over
Meal-kit maker Blue Apron's (NYSE: APRN) public debut in late June was one of the most disappointing IPOs in recent history. The company went public at $10 per share, but it's already shed about a
Why Electronic Arts' Stock Soared 34% in 2017 So Far
Video game publisher Electronic Arts (NASDAQ: EA) stock gained 34% through the first half 2017, according to data provided by S&P Global Market Intelligence.The rally sent shares to new record highs
Why Electronic Arts' Stock Soared 34% in 2017 So Far
Video game publisher Electronic Arts (NASDAQ: EA) stock gained 34% through the first half 2017, according to data provided by S&P Global Market Intelligence.The rally sent shares to new record highs
Why Electronic Arts' Stock Soared 34% in 2017 So Far
Video game publisher Electronic Arts (NASDAQ: EA) stock gained 34% through the first half 2017, according to data provided by S&P Global Market Intelligence.The rally sent shares to new record highs
Disney's D23 Gives Star Wars Fans a New Hope
Since buying Lucasfilm in 2012, Walt Disney (NYSE: DIS) has not only restored the luster of the Star Wars franchise, but it has also grown the fan base.The company has released two well-received films
Disney's D23 Gives Star Wars Fans a New Hope
Since buying Lucasfilm in 2012, Walt Disney (NYSE: DIS) has not only restored the luster of the Star Wars franchise, but it has also grown the fan base.The company has released two well-received films
3 Things Cirrus Logic Management Wants You to Know
Cirrus Logic (NASDAQ: CRUS) develops hardware and software for audio and voice signal processing. And while the details of what these products do can get pretty complicated, the company's business
3 Things Cirrus Logic Management Wants You to Know
Cirrus Logic (NASDAQ: CRUS) develops hardware and software for audio and voice signal processing. And while the details of what these products do can get pretty complicated, the company's business
3 Things Cirrus Logic Management Wants You to Know
Cirrus Logic (NASDAQ: CRUS) develops hardware and software for audio and voice signal processing. And while the details of what these products do can get pretty complicated, the company's business
3 Things Cirrus Logic Management Wants You to Know
Cirrus Logic (NASDAQ: CRUS) develops hardware and software for audio and voice signal processing. And while the details of what these products do can get pretty complicated, the company's business
Mondelez International History: Everything Investors Need to Know
In October 2012, Kraft Foods split itself into two separate publicly traded companies: Mondelez International (NASDAQ: MDLZ) and Kraft Foods Group, which is now part of Kraft Heinz. Kraft Foods
Mondelez International History: Everything Investors Need to Know
In October 2012, Kraft Foods split itself into two separate publicly traded companies: Mondelez International (NASDAQ: MDLZ) and Kraft Foods Group, which is now part of Kraft Heinz. Kraft Foods
Mondelez International History: Everything Investors Need to Know
In October 2012, Kraft Foods split itself into two separate publicly traded companies: Mondelez International (NASDAQ: MDLZ) and Kraft Foods Group, which is now part of Kraft Heinz. Kraft Foods
This Is Why Investors Will Need to Learn a New Acronym: CRISPR
In this Market Foolery segment, host Chris Hill and Motley Fool Rule Breakers' Aaron Bush talk about where genetic engineering is heading -- which is out of the lab and toward really curing diseases
How Safe Is Chevron's Dividend?
Chevron (NYSE: CVX) is one of the largest oil and gas companies in the world, and it has grown substantially over the course of its long history. All energy companies are susceptible to the ups and
How Safe Is Chevron's Dividend?
Chevron (NYSE: CVX) is one of the largest oil and gas companies in the world, and it has grown substantially over the course of its long history. All energy companies are susceptible to the ups and
3 Stocks With Colossal Business Advantages
With great business advantages come great long-term stock returns. The company doesn't have to cheat -- just tip the scales in its own favor with the help of regular business tools.We asked a panel of
3 Small Biotech Stocks Being Run by Proven Winners
Great leaders are important in any industry, but perhaps they're even more valuable in biotech, where any number of clinical-stage and regulatory obstacles can derail drug research and send share